IDYAHIGH SIGNALFINANCIAL10-K

IDYA experienced explosive revenue growth of over 3,000% to $218.7M while simultaneously cutting losses in half, signaling a major business transformation.

This dramatic revenue surge combined with significant loss reduction suggests IDYA has achieved a major commercial breakthrough or licensing milestone that fundamentally changes its financial profile. The removal of standard biotech risk language about competition and development challenges, coupled with new partnership references to major pharma companies, indicates the company may have transitioned from early-stage development to commercial execution or major deal realization.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

IDYA's financials show a remarkable transformation with revenue exploding from $7M to $218.7M while losses were cut nearly in half from -$274.5M to -$113.7M in net income. Operating cash flow improved dramatically by 71% to -$71.1M, and the company strengthened its balance sheet with cash increasing 34% to $112.8M despite higher liabilities. This combination of massive revenue growth, improving profitability metrics, and stronger cash position suggests IDYA has achieved a significant commercial milestone or partnership deal that has fundamentally altered its business trajectory.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+3024.4%
$7.0M→$218.7M

Strong top-line growth of 3024.4% — accelerating demand or successful expansion into new markets.

Operating Cash Flow
Cash Flow
+71.3%
-$247.6M→-$71.1M

Operating cash flow surged 71.3% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+58.6%
-$274.5M→-$113.7M

Net income grew 58.6% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+51.3%
-$327.0M→-$159.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
-38.6%
$3.9M→$2.4M

Capex reduced 38.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+33.7%
$84.4M→$112.8M

Cash position surged 33.7% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
+33%
$64.9M→$86.4M

Liabilities grew 33% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+27.7%
$46.1M→$58.8M

Current liabilities rose 27.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
As of February 13, 2026, the registrant had 87,814,027 shares of common stock, $0.0001 par value per share, outstanding.
This number does not include 875,135 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of February 13, 2026 (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations).
(Gilead), our Clinical Trial Collaboration and Supply Agreements with Pfizer Inc.
(Pfizer), our License Agreement with Novartis, our Option and License Agreement with Cancer Research Technologies Ltd.
and the University of Manchester, our Option and License Agreement with Biocytogen ii Pharmaceuticals (Beijing) Co.
+7 more — sign up free →
REMOVED
As of February 14, 2025, the registrant had 87,537,391 shares of common stock, $0.0001 par value per share, outstanding.
We have incurred significant losses since our inception, and we anticipate that we will iii continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability; We are early in our development efforts.
Furthermore, results of earlier studies and trials may not be predictive of future trial results; We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed.
This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts; We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration.
Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete; If we fail to attract and retain senior management and key scientific and commercial personnel, our business may be materially and adversely affected; Our success depends on our ability to obtain and maintain protection for our intellectual property and our proprietary technologies and to avoid infringing the rights of others; and Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →